Response-adapted zanubrutinib and tislelizumab as a potential strategy to enhance CD19 CAR T-cell therapy in relapsed/refractory large B-cell lymphoma: A retrospective observational study.
反应适应性 zanubrutinib 和 tislelizumab 作为增强 CD19 CAR T 细胞疗法治疗复发/难治性大 B 细胞淋巴瘤的潜在策略：一项回顾性观察研究
期刊:Clinical and Translational Medicine
影响因子:6.8
doi:10.1002/ctm2.70310
Shen Rong, Cao Wei-Guo, Wang Li, Sheng Ling-Shuang, Zhang Yi-Lun, Wu Wen, Xu Peng-Peng, Cheng Shu, Liu Meng-Ke, Dong Yan, Wang Yue, Weng Xiang-Qin, Jiang Xu-Feng, Song Qi, Yi Hong-Mei, Li Lei, Chen Sheng, Yan Zi-Xun, Zhao Wei-Li
